Cangrelor Advisory Cmte. Unsure Whether Plavix Even Needs Replacing
Executive Summary
After a brutal panel review, The Medicines Co.’s best chance for its anti-clotting medication may be to create a “better sense of the unmet need” in the perioperative setting when Plavix use must be suspended.
You may also be interested in...
Cangrelor Survives Second Advisory Committee, But Narrowly
FDA panel members were not enthusiastic about the antiplatelet, but felt it could help ‘some people.’
The Medicines Co.’s Slimmer Cangrelor Filing Slated For April Panel Review
Company believes it has addressed all of FDA’s concerns in an April 2014 “complete response” letter relative to use during percutaneous coronary intervention, the only indication that will be the focus of a second advisory committee review.
FDA’s Cangrelor “Complete Response” Leaves Room For Approval Without New Trial
Agency requests additional analyses, but not a new study, supporting the antiplatelet’s use in patients undergoing percutaneous coronary intervention, The Medicines Co. says. However, a second indication in stent thrombosis patients who must stop oral antiplatelet therapy would require a new outcomes trial.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: